Study
New study launched within the AIDA Network: deadline extended to March 16, 2026
A new collaborative study has been initiated within the AIDA Network to investigate the use of combination therapy with two biologic agents or with a biologic agent plus a JAK inhibitor in patients with refractory arthritis.
The study aims to confirm preliminary single-center findings in a larger international cohort (doi:10.1007/s11739-026-04274-5).
All forms of arthritis may be included, including cases associated with systemic diseases (such as Behçet’s disease, familial Mediterranean fever, and other inflammatory conditions).
Given the expected rarity of such cases, colleagues interested in participating are kindly invited to confirm their availability and submit the requested data by February 28, 2026.
For further information, please contact: support@aidanetwork.org